Mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Schnitzer (1927), arts teacher and administrator Francis Steegmuller (1927), Flaubert scholar Gustave Von Groschwitz (1927), former director of the Carnegie Museum of Art Carl Benjamin Boyer (1928), historian of science and mathematics Leon Keyserling (1928), head of the Council of Economic Advisers under Harry S Truman Edgar Lorch (1928), mathematics department chairman at Columbia University Junius Bird (1930), archaeologist and former curator of South American Archaeology at the American Museum of Natural History Eli Ginzberg (1930), professor of economics at Columbia University Niels Henry Sonne (1930), rare book collector and head librarian at General Theological Seminary Maxwell Geismar (1931), literary critic, author, and professor at Sarah Lawrence College Francis Joseph Murray (1932), mathematician who developed the Von Neumann algebra with John von Neumann Walter H. Rubsamen (1933), professor of a musicology at the University of California, Los Angeles Joseph Leon Blau (1934), professor of religion at Columbia University M. A. Fitzsimons (1934), historian at the University of Notre Dame, editor of The Review of Politics Alan Gewirth (1934), philosopher, professor of philosophy at the University of Chicago, author of Reason and Morality Robert M.
== Books, documentaries, and miniseries == John Carreyrou, a Wall Street Journal journalist whose work exposed Theranos, published a book-length treatment in May 2018 titled Bad Blood: Secrets and Lies in a Silicon Valley Startup. A film version was reportedly scheduled for release in 2020, starring Jennifer Lawrence as Holmes, written by Vanessa Taylor and directed by Adam McKay. In January 2022, McKay stated that preparations for the film had resumed, and that Lawrence was working on learning Holmes's speech pattern. However, in November 2022, Lawrence announced she would no longer be involved with the project. In January 2019, ABC News Nightline released a podcast and documentary about the Holmes/Theranos story called The Dropout. A biographical miniseries with the same name, based on the eponymous podcast, premiered on Hulu in the US, Star+ in Latin America and Disney+ internationally in March 2022, with Amanda Seyfried as Holmes. Also in January 2019, a documentary film entitled The Inventor: Out for Blood in Silicon Valley about Holmes and Theranos was released. Directed by Alex Gibney, it made its debut at the Sundance Film Festival and was released March 2019 on HBO platforms. You Can See Everything, a documentary in which Elizabeth Holmes and partner Billy Evans invited filmmaker Nathan Fielder and co-director Lance Oppenheim to spend time with them, will be released on October 16, 2026.
== Diversity-oriented libraries == Even though combinatorial chemistry has been an essential part of early drug discovery for more than two decades, so far only one de novo combinatorial chemistry-synthesized chemical has been approved for clinical use by FDA (sorafenib, a multikinase inhibitor indicated for advanced renal cancer). The analysis of the poor success rate of the approach has been suggested to connect with the rather limited chemical space covered by products of combinatorial chemistry. When comparing the properties of compounds in combinatorial chemistry libraries to those of approved drugs and natural products, Feher and Schmidt noted that combinatorial chemistry libraries suffer particularly from the lack of chirality, as well as structure rigidity, both of which are widely regarded as drug-like properties. Even though natural product drug discovery has not probably been the most fashionable trend in the pharmaceutical industry in recent times, a large proportion of new chemical entities still are nature-derived compounds, and thus, it has been suggested that effectiveness of combinatorial chemistry could be improved by enhancing the chemical diversity of screening libraries. As chirality and rigidity are the two most important features distinguishing approved drugs and natural products from compounds in combinatorial chemistry libraries, these are the two issues emphasized in so-called diversity oriented libraries, i.e. compound collections that aim at coverage of the chemical space, instead of just huge numbers of compounds.
Sources: en.wikipedia.org
== Further reading == Hunt, Chris; et al. (August 28, 2023). "Shanidar et ses fleurs? Reflections on the palynology of the Neanderthal 'Flower Burial' hypothesis". Journal of Archaeological Science. 159 105822. Bibcode:2023JArSc.159j5822H. doi:10.1016/j.jas.2023.105822. S2CID 261325698. Pettitt, Paul; White, Mark (2012). The British Palaeolithic: hominin societies at the edge of the Pleistocene world. London: Routledge. ISBN 978-0-415-67454-6. Romagnoli, Francesca; Rivals, Florent; Benazzi, Stefano (2022). Updating Neanderthals: Understanding Behavioural Complexity in the Late Middle Palaeolithic. Academic Press. ISBN 978-0-12-821429-9. Stringer, C.; Gamble, C. (1993). In search of the Neanderthals. Thames and Hudson. ISBN 0-500-05070-8. Sykes, Rebecca Wragg (2020). Kindred: Neanderthal Life, Love, Death and Art. London: Bloomsbury Sigma. ISBN 978-1-4729-3749-0.
Ginkgo has long been cultivated in China. It is common in the southern third of the country. Some planted trees at temples are believed to be over 1,500 years old. The first record of Europeans encountering it is in 1690 in Japanese temple gardens, where the tree was seen by the German botanist Engelbert Kaempfer. Because of its status in Buddhism and Confucianism, the ginkgo has also been widely planted in Korea and in Japan since the 14th century; in both areas, some naturalization has occurred, with ginkgos seeding into natural forests. Ginkgo has been commonly cultivated in North America for over 200 years and in Europe for close to 300, but during that time, it has never become significantly naturalized. G. biloba is also commonly manually planted in cities across the United States and Europe. This species is highly tolerant to pollution and serves as a visually appealing, shade-providing tree in many cities and gardens. Many intentionally planted ginkgos are male cultivars grafted onto plants propagated from seed, because the male trees will not produce the malodorous seeds. The popular cultivar 'Autumn Gold' is a clone of a male plant. The disadvantage of male Ginkgo biloba trees is that their pollen is highly allergenic. They have an OPALS (Ogren Plant Allergy Scale) rating of 7 (out of 10), whereas female trees, which can produce no pollen, have an OPALS allergy scale rating of 2.
ILMs have a calcium regulation system profile suggestive of a better ability to handle calcium changes in comparison to other muscles, and this may provide a mechanistic insight for their unique pathophysiological properties. In addition, patients with Duchenne muscular dystrophy also have elevated plasma lipoprotein levels, implying a primary state of dyslipidemia in patients.
1993/1130) Dundee Teaching Hospitals National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1131) Caithness and Sutherland National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1132) Southern General Hospital National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1133) Stirling Royal Infirmary National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1134) Victoria Infirmary National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1135) West Lothian National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1136) Yorkhill National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1137) North Ayrshire and Arran National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1138) Monklands and Bellshill Hospitals National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1139) Ayrshire and Arran Community Health Care National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1140) Essex and Greater London (County and London Borough Boundaries) Order 1993 (S.I. 1993/1141) Croydon, Lambeth and Southwark (London Borough Boundaries) Order 1993 (S.I. 1993/1147) Greater London and Surrey (County and London Borough Boundaries) Order 1993 (S.I. 1993/1148) Coast Protection (Variation of Excluded Waters) Regulations 1993 (S.I. 1993/1149) Income-related Benefits Schemes (Miscellaneous Amendments) (No. 2) Regulations 1993 (S.I.
Sources: en.wikipedia.org
== Spectroscopy == A random-coil conformation can be detected using spectroscopic techniques. The arrangement of the planar amide bonds results in a distinctive signal in circular dichroism. The chemical shift of amino acids in a random-coil conformation is well known in nuclear magnetic resonance (NMR). Deviations from these signatures often indicates the presence of some secondary structure, rather than complete random coil. Furthermore, there are signals in multidimensional NMR experiments that indicate that stable, non-local amino acid interactions are absent for polypeptides in a random-coil conformation. Likewise, in the images produced by crystallography experiments, segments of random coil result simply in a reduction in "electron density" or contrast. A randomly coiled state for any polypeptide chain can be attained by denaturing the system. However, there is evidence that proteins are never truly random coils, even when denatured (Shortle & Ackerman).
Following Enoch Powell's Rivers of Blood speech Heseltine publicly urged Heath to deal firmly with him—to the consternation of many in his local party at Tavistock, where Powell enjoyed strong support. Three days later, Heseltine was one of around two dozen Conservative MPs who defied the whip to abstain rather than vote against the second reading of the 1968 Race Relations Bill (which banned racial discrimination). He argued that the Conservatives should state their own alternative policy rather than just oppose. Heseltine was promoted to principal opposition spokesman on transport in November 1969, although unlike his predecessors Thatcher and Walker, he was not a member of the Shadow Cabinet. He went on a six-week tour of India, Hong Kong, Singapore, Australia and the US to study how their docks were run, in readiness for Labour's planned 1970 Docks Bill (which in the event was cancelled because of that year's general election).
== Production == The manufacturing process of pea protein concentrates and isolates consists of protein extraction, purification, and drying. The industrial production of pea protein begins with the steps of cleaning and splitting the pea crop and then processing them further. The cleaning process: Cleaning uses equipment such as indent cleaners, which are used to remove impurities. This process ensures that any allergens, such as wheat, barley and other seeds are removed, as these products contain gluten. If not removed, it would affect its classification as a gluten-free product. The splitting process: Following cleaning, the pea is split and "dehulled" using a dehuller. The dehullers are a device that splits the pea seed and extracts the part of the whole seed which is the hull. Further processing: Following the splitting process, the split peas are further processed either into starch, protein, and flour fractions. Pea protein can be produced using two methods:
The events within the cell that cause disordered pituitary cell growth and GH oversecretion currently are the subject of intensive research. Pituitary adenomas and diffuse somatomammotroph hyperplasia may result from somatic mutations activating GNAS, which may be acquired or associated with McCune–Albright syndrome.
=== Deputy Leaders of the Liberal Party in the House of Lords === Eric Drummond, 7th Earl of Perth (1946–1951) Walter Layton, 1st Baron Layton (1952–1955) Post vacant (1955–1965) Gladwyn Jebb, 1st Baron Gladwyn (1965–1988)
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.